/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and.
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.